Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer’s Announcement
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Pfizer has just announced that a person with hemophilia, in their marstacimab (Hympavzi) clinical trial program, has died from a thrombotic stroke.
I attach the letter they sent to a number of patient organisations including the World Federation of Hemophilia.
The information provided in the letter is minimal.
I hope they reach out to all hemophilia doctors worldwide who can potentially prescribe this drug to inform them about this event, and the other thrombotic event in the same clinical trial that was previously disclosed at the EAHAD and ISTH meetings.
The patient who died, had hemophilia A with an inhibitor.
Marstacimab is at present only approved for persons with hemophilia A and B without an inhibitor.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers